Nasdaq rxrx.
The firm has a market cap of $2.09 billion, a PE ratio of -6.60 and a beta of 0.63. Recursion Pharmaceuticals ( NASDAQ:RXRX – Get Free Report) last announced its earnings results on Thursday ...
Recursion Pharmaceuticals (NASDAQ: RXRX) hit headlines hard earlier in the year as artificial intelligence giant Nvidia announced a $50 million direct investment in the biotech stock.A high-level overview of Recursion Pharmaceuticals, Inc. (RXRX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Find the latest historical data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.Jan 8, 2024 · Recursion Pharmaceuticals (RXRX) shares rallied 7.4% in the last trading session to close at $11.93. This move can be attributable to notable volume with a higher number of shares being traded ...
Recursion Pharma (NASDAQ: RXRX) made waves this week.On Wednesday, the firm reported a hefty $50 million cash infusion from Nvidia to support efforts in developing AI models that speed up drug ...Get the latest Recursion Pharmaceuticals Inc (RXRX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...
Although the biotech company missed revenue consensus, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) saw a 150% increase in revenue in the third quarter to $2.5 million in Q3 2021, up from $1 ...Jan 19, 2024 · A. The latest price target for Recursion Pharmaceuticals ( NASDAQ: RXRX) was reported by Needham on Wednesday, January 17, 2024. The analyst firm set a price target for 15.00 expecting RXRX to ...
December 9, 2023 at 11:06 AM · 4 min read. In a notable insider transaction, CEO Christopher Gibson sold 59,829 shares of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) on December 6, 2023. This ...Jan 21, 2024 · Platinum Investment Management Ltd. lessened its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 13.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,335,132 shares of the compa Recursion Pharmaceuticals (RXRX) Insider Trading & Ownership. $10.26. -0.50 (-4.65%) (As of 01/17/2024 ET) Stock Analysis Analyst Forecasts Chart Competitors …Find the latest analyst research for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. ... Based on analysts offering 12 month price targets for RXRX in the last 3 months. Feb 17, 2023 · Recursion Pharmaceuticals (NASDAQ:RXRX) - the subject of this analysis - IPOd in April 2021, issuing 27.88m shares at a price of $18 per share, and raising >$500m - making it the sixth largest ...
Institutional investors have sold a total of 19,621,281 shares in the last 24 months. This volume of shares sold represents approximately $160.50M in transactions. Related Companies: ImmunityBio Institutional Ownership. Neumora Therapeutics Institutional Ownership. This page (NASDAQ:RXRX) was last updated on 1/15/2024 …
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...
Nov 26, 2023 · For a biotech like Recursion Pharmaceuticals (RXRX-2.63%) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and development, computing power is a key ... SALT LAKE CITY, April 11, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that the U.S ...Recursion Pharmaceuticals has a market capitalisation of US$1.9b and burnt through US$113m last year, which is 6.0% of the company's market value. Given that is a rather small percentage, it would ...Recursion Pharmaceuticals, Inc. (RXRX) High-Resolution Genome-Wide Mapping of Chromosome-Arm-Scale Truncations Induced by CRISPR-Cas9 Editing CRISPR-Cas9 editing is a scalable technology for mapping of biological pathways, but it has been reported to cause a variety of undesired large-scale structural changes to the genome. Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel ...Jan 8, 2024 · SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today presented a ...
Feb 17, 2023 · Recursion Pharmaceuticals (NASDAQ:RXRX) - the subject of this analysis - IPOd in April 2021, issuing 27.88m shares at a price of $18 per share, and raising >$500m - making it the sixth largest ... Find the latest analyst research for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. ... Based on analysts offering 12 month price targets for RXRX in the last 3 months. Dec 14, 2023 · Clinical-stage biotech companies often take time to be profitable. Recursion's total revenue in Q3 dipped to $10.5 million compared to $13.2 million in Q3 2022. Its net loss in the quarter came in ... SALT LAKE CITY , Nov. 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conference: Jefferies London Healthcare Conference – November 14-16,Get the latest Recursion Pharmaceuticals Inc (RXRX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment... Ignatiev. At a Glance. Recursion Pharmaceuticals (NASDAQ:RXRX) is carving out a vanguard role in TechBio by synergizing wet-lab biology with advanced computational tools.The firm's Q2 earnings ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the latest acquisitions of Harvard Management Company as the fund bought over 1.5 million shares of the company worth $55.08 million in Q2 2021.REC-2282 is developed for the treatment of neurofibromatosis type 2. paper trading platform. Webull offers RXRX Ent Holdg (RXRX) historical stock prices, in-depth market analysis, NASDAQ: RXRX real-time stock quote data, in-depth charts, free RXRX options chain data, and a fully built financial calendar to help you invest smart.
Health Care Sector Update for 01/04/2024: SEM, XERS, RXRX, OMGA, NVO January 04, 2024 — 03:53 pm EST Written by MT Newswires for MTNewswires ->Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the latest acquisitions of Harvard Management Company as the fund bought over 1.5 million shares of the company worth $55.08 million in Q2 2021.Jul 17, 2023 · Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from artificial intelligence (AI) ... May 29, 2023 · On May 8, Recursion Pharmaceuticals (RXRX-2.63%) announced that it was going to buy a pair of AI-enabled drug discovery biotechs, Cyclica and Valence, for a total of $87.5 million -- paid in stock. Recursion Pharmaceuticals (NASDAQ: RXRX) exploded in July on the strength of hot news—a $50 million direct investment from Nvidia (NASDAQ: NVDA). Since that month’s high, shares are back in ...Shares of Recursion Pharmaceuticals ( NASDAQ: RXRX) climbed on Thursday after the AI-led biotech announced a licensing agreement with German conglomerate Bayer ( OTCPK:BAYZF) to in-license a new ...Jan 19, 2024 · Financial Performance. In 2022, RXRX's revenue was $39.84 million, an increase of 291.46% compared to the previous year's $10.18 million. Losses were -$239.48 million, 28.4% more than in 2021. Financial Statements.
Dec 14, 2023 · Clinical-stage biotech company Recursion Pharmaceuticals (NASDAQ:RXRX) might be a relatively small company, but it’s taking significant steps toward a stronger future. Wall Street currently ...
The idea of Recursion Pharmaceuticals (RXRX-4.65%) is to throw petabytes of data on biological targets, chemical interactions, and bioactive molecules at a machine learning platform to identify ...
Jul 13, 2023 · Over the past 3 months, 6 analysts have published their opinion on Recursion Pharmaceuticals (NASDAQ:RXRX) stock. These analysts are typically employed by large Wall Street banks and tasked with ... Fintel reports that on May 9, 2023, Needham reiterated coverage of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) with a Buy recommendation.. Analyst Price Forecast Suggests 206.61% Upside. As of ...Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.34 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.33 per share a year ago. These figures are ...Jan 4, 2024 · Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ... Shafique Virani, Chief Business Officer of Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 18,000 shares of the company on January 16, 2024, according to a recent SEC Filing ... SALT LAKE CITY, April 11, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that the U.S ...Recursion Pharmaceuticals: More Hype Than Substance (NASDAQ:RXRX) | Seeking Alpha Join the community. Try Seeking Alpha for free by creating an account» …All Rights Reserved. Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global …Overview Financials News Ideas Technicals Forecast RXRX chart Today −3.58% 5 days −13.64% 1 month 12.08% 6 months −29.95% Year to date 11.16% 1 year 25.41% 5 years …
November 10, 2023 at 5:06 AM · 3 min read. With a price-to-sales (or "P/S") ratio of 23.8x Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX) may be sending very bearish signals at the moment, given ...The stock price for . Recursion Pharmaceuticals (NASDAQ: RXRX) is $9.98 last updated Today at January 18, 2024 at 7:59 PM EST. Q Does Recursion …Oct 14, 2021 · The big shareholder groups in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see ... Instagram:https://instagram. culverandif clear blue says 1 2 weeks how far am iinnovationjak sie przygotowac do budowy domu Shafique Virani, Chief Business Officer of Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 18,000 shares of the company on January 16, 2024, according to a recent SEC Filing. Get the latest ... quarter thatsullivanpercent27s island The average one-year price target for Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) has been revised to 17.17 / share. This is an increase of 7.12% from the prior estimate of 16.03 dated August 31 ...Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. tv 9and10 weather Find the latest news headlines from Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.Shares of NASDAQ:RXRX opened at $10.23 on Friday. Recursion Pharmaceuticals, Inc. has a 52 week low of $4.54 and a 52 week high of $16.75. The firm’s 50 day moving average is $9.27 and its two ...In the previous quarter, Recursion Pharmaceuticals (NASDAQ:RXRX) missed the analysts' consensus estimate of ($0.38) by $0.05 with a reported earnings per share (EPS) of ($0.43). Learn more on analysts' earnings estimate vs. RXRX's actual earnings.